期刊文献+

肺癌患者化疗前后NSE、SIL-2R和TNF测定的临床意义 被引量:3

Clinical Significance of Determination of Changes of Serum NSE,SIL-2R and TNF Levels in Patients with Lung Cancer Undergoing Chemotherapy
暂未订购
导出
摘要 目的:探讨33例肺癌患者中28人化疗前后血清中NSE、TNF含量的变化。方法:应用放射免疫分析检测33例肺癌患者化疗前后血清NSE和TNF含量,酶联免疫分析测定SIL-2R含量并与30名正常健康人作比较。结果:肺癌患者化疗前血清中NSE、SIL-2R和TNF含量均非常显著地高于正常人组(P<0.01)。化疗后,6个月在未复发的20例中明显下降但仍高于对照组,而复发的8例,其数值又回升至化疗前水平(P<0.05)。结论:检测肺癌患者血清NSE、SIL-2R和TNF含量的变化可作为诊断和疗效观察的参考。 Objective To detect the changes of serum NSE, SIL - 2R and TNF levels in the 33 patients with lung cancer undergoing chemotherapy. Methods Serum NSE, SIL- 2R and TNF levels were determined with RIA and SIL- 2R levels with ELISA in 33 lung cancer patients both before and after chemotherapy ( n = 28 ) as well as in 30 controls. Results Before chemotherapy, serum NSE, SIL - 2R and TNF levels in the patients were significantly higher than those in the controls (P 〈 0.01 ). After chemotherapy, in 20 cases without recurence at 6 months, the levels were much lower but still significantly higher than those in controls ( P 〈 0.05 ). However, in the 8 patients with recurrence, the levels increased again to approaching those before chemotherapy. Conclusion Serum levels of NSE, SIL- 2R and TNF might be useful for diagnosis and predicting therapeutic effects after chemotherapy in patients with lung cancer.
作者 谭宗宪
出处 《放射免疫学杂志》 CAS 2005年第4期285-286,共2页 Journal of Radioimmanology
关键词 肺癌 化学治疗 实验室检查 神经元特异性烯醇化酶 白细胞介素-2受体 肿瘤坏死因子 lung cancer, neuron specific enolase ( NSE), serum interleukin-2 receptor ( SIL - 2R), tumor necrcosis factor(TNF)
  • 相关文献

参考文献8

二级参考文献3

共引文献136

同被引文献23

  • 1芮志莲.肺癌患者化疗前后血清SIL-2R,CEA含量检测的临床意义[J].放射免疫学杂志,2004,17(5):356-357. 被引量:13
  • 2沈德美,许凤.中西医结合治疗晚期非小细胞肺癌疗效观察[J].上海中医药杂志,2005,39(8):5-6. 被引量:6
  • 3任亮,顾涛,徐洁洁.鼻咽癌患者放疗前后血清SE-cad、IL-2、SIL-2R和TNF-α检测的临床意义[J].放射免疫学杂志,2006,19(5):373-375. 被引量:8
  • 4Demagala-Kulaw ik J,Hoser G,Droszcz P,et al.T-cell subtypes in bronehoalveo lar lavage fluid and in peripheral blood from patients with primary lug cancer[J].Diagn Cytopathol,2001,25(4):2082-2083
  • 5Marine P,buceheri G,Preatoni A,et al.Soluble interleukin-2 receptor.a new prognostic marker in lung cancer[J].J Nud MED Allied Sci,1990,30:151
  • 6tey A,Klein B,zagury D,et al.Diminished interleukin-2 activity production in cancer patients beating solid tumords and its relationship with matural killer cells[J].Immunol Lett,1983,6(3):175
  • 7Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review[J]. JAMA, 2012, 307(22): 2418-2429.
  • 8Griggs JJ, Mangu PB, Anderson H, et al. Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline[J]. J Clin Oncol, 2012, 30(13): 1553-1561.
  • 9Qiu FM, Li ZP, Huang J. Research progress of gammadelta T cell-based immunotherapy[J]. Zhejiang Da Xue Xue Bao Yi Xue Ban, 2010, 39(4): 424-429.
  • 10Bayliss TJ, Smith JT, Schuster M, et al. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer[J]. Expert Opin Biol Ther, 2011, 11(12): 1663-1668.

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部